Table 2:
Therapeutic management and outcomes.
| Whole cohort, N = 241 | WEE, N = 221 | Early ESKD, N = 20 | |
|---|---|---|---|
| Therapeutic management Induction | |||
| Plasma exchange | 58 (24) | 50 (23) | 8 (40) |
| Intravenous corticosteroids | 203 (85) | 184 (84) | 19 (95) |
| Oral corticosteroids | 234 (99) | 214 (99) | 20 (100) |
| Cyclophosphamide | 177 (74) | 158 (72) | 19 (95) |
| Rituximab | 50 (21) | 49 (22) | 1 (5.3) |
| Maintenance | |||
| Corticosteroids | 235 (98) | 215 (98) | 20 (100) |
| Rituximab | 126 (53) | 123 (57) | 3 (15) |
| Azathioprine | 112 (47) | 103 (47) | 9 (45) |
| Follow-up duration (months) | 59 (30–111) | 61 (32–113) | 28 (20–74) |
| Kidney replacement therapy (KRT) | |||
| At least once during follow-up | 81 (34) | 61 (28) | 20 (100) |
| KRT within 30 days from diagnosis | 44 (18) | 25 (11) | 19 (95) |
| KRT duration | |||
| Never | 159 (66) | 159 (72) | 0 (0) |
| Less than 3 months | 19 (7.9) | 19 (8.6) | 0 (0) |
| More than 3 months (ESKD) | 62 (26) | 42 (19) | 20 (100) |
| Biological parameters at 6 months | |||
| Creatinine (μmol/L) | 136 (110–204) | 136 (110–204) | |
| eGFR (mL/min) | 36 (20–54) | 38 (24–55) | |
| ΔeGFR M0–M6 | +10 (1–20) | ||
| Proteinuria (g/g) | 0.70 (0.26–1.46) | 0.64 (0.26–1.44) | 4.37 (3.58–5.15) |
| Presence of hematuria | 69 (54) | 65 (54) | 4 (50) |
| CRP (mg/L) | 4 (4–10) | 4 (4–10) | 8 (7–36) |
| ANCA-positive at 6 months | 83 (70) | 78 (68) | 5 (100) |
| Relapses | 75 (32) | 71 (33) | 4 (20) |
| With kidney involvement | 47 (62.7) | 45 (63.4) | 2 (10) |
| Kidney survival | |||
| ESKD during follow-up | 62 (26) | 42 (19) | 20 (100) |
| ESKD at diagnosis | 18 (7.5) | 0 (0) | 18 (90) |
| Overall survival (death) | 66 (28) | 55 (25) | 11 (55) |
Data are presented as median (1st–3rd quartile) or n (%).
CRP: C-reactive Protein; M0: at diagnosis; M6: at 6 months.